| | | Beta-blockers n = 44,404 | ACEi n = 132,545 | ARB n = 12,018 | CCB n = 91,731 | Diuretics n = 106,547 |
| | Demographic characteristics | | Age (years) | | | | | | | Median (p25; p75) | 57 (49; 68) | 54.0 (47; 64) | 57.0 (49; 67) | 64.0 (57; 72) | 66.0 (56; 74) | | <55, n (%) | 18,363 (41.4%) | 67,719 (51.1%) | 5,039 (41.9%) | 17,480 (19.1%) | 22,160 (20.8%) | | ≥55, n (%) | 26,041 (58.6%) | 64,826 (48.9%) | 6,979 (58.1%) | 74,251 (80.9%) | 84,387 (79.2%) | | Sex | | | | | | | Male, n (%) | 22,250 (50.1%) | 77,069 (58.1%) | 6,822 (56.8%) | 47,617 (51.9%) | 42,396 (39.8%) |
| | Clinical characteristics | | Time since HTN diagnosis (years) | | | | | | | Median (p25; p75) | 0.1 (0.0; 4.6) | 0.0 (0.0; 0.1) | 0.0 (0.0; 2.7) | 0.0 (0.0; 0.1) | 0.0 (0.0; 1.4) | | Systolic BP (mmHg) | | | | | | | Median (q1; q3) | 163 (150; 180) | 160 (150; 172) | 160 (150; 176) | 165 (155; 180) | 167 (155; 180) | | ≥140 | 35,772 (88.4%) | 118,820 (92.5%) | 10,277 (90.8%) | 83,312 (94.8%) | 95,082 (94.6%) | | Missing, n (%) | 3,932 (8.9%) | 4,071 (3.1%) | 701 (5.8%) | 3,809 (4.2%) | 6,074 (5.7%) | | Diastolic BP (mmHg) | | | | | | | Median (p25; p75) | 96 (88; 104) | 96 (90; 102) | 95 (88; 101) | 94 (86; 100) | 94 (86; 100) | | ≥90 | 29,546 (73.0%) | 98,048 (76.3%) | 8,278 (73.1%) | 60,044 (68.3%) | 70,566 (70.2%) | | Missing, n (%) | | | | | | | BMI (kg/m2) | 3,946 (8.9%) | 4,076 (3.1%) | 694 (5.8%) | 3,809 (4.2%) | 6,080 (5.7%) | | Median (p25; p75) | 28.2 (25.1; 31.8) | 29.6 (26.3; 33.5) | 28.9 (25.8; 32.8) | 28.2 (25.1; 31.8) | 27.9 (24.9; 31.6) | | <25, n (%) | 3,975 (23.6%) | 11,576 (15.8%) | 1,072 (19.4%) | 10,325 (23.9%) | 11,659 (25.8%) | | 25–29, n (%) | 6,727 (39.9%) | 26,739 (36.6%) | 2,118 (38.3%) | 17,118 (39.6%) | 17,987 (39.7%) | | ≥30, n (%) | 6,148 (36.5%) | 34,763 (47.6%) | 2,344 (42.4%) | 15,744 (36.5%) | 15,631 (34.5%) | | Missing, n (%) | 27,554 (62.1%) | 59,467 (44.9%) | 6,484 (54.0%) | 48,544 (52.9%) | 61,269 (57.5%) | | GFR | | | | | | | Median (p25; p75) | 74.2 (62.5; 86.2) | 77.2 (61.1; 90.0) | 73.9 (60.0; 87.0) | 72.5 (60.0; 85.5) | 70.4 (60.0; 82.5) | | Missing, n (%) | 24,317 (54.8%) | 37,143 (28.0%) | 5,086 (42.3%) | 33,899 (37.0%) | 51,210 (48.1%) |
| | Smoking status | | Current smoker, | | | | | | | n (%) | 9,013 (20.3%) | 27,749 (20.9%) | 2,145 (17.8%) | 16,635 (18.1%) | 20,591 (19.3%) |
| | Comorbidities and co-medications | | Disease of the circulatory system, n (%) | | | | | | | Angina | 1,257 (2.8%) | 385 (0.3%) | 50 (0.4%) | 564 (0.6%) | 479 (0.4%) | | Arrhythmia | 1,245 (2.8%) | 787 (0.6%) | 110 (0.9%) | 701 (0.8%) | 862 (0.8%) | | Atrial fibrillation | 1,071 (2.4%) | 723 (0.5%) | 103 (0.9%) | 608 (0.7%) | 805 (0.8%) | | Chronic heart failure | 57 (0.1%) | 240 (0.2%) | 17 (0.1%) | 25 (0.0%) | 412 (0.4%) | | Myocardial infarction | 406 (0.9%) | 317 (0.2%) | 14 (0.1%) | 58 (0.1%) | 95 (0.1%) | | Peripheral vascular disease | 96 (0.2%) | 637 (0.5%) | 57 (0.5%) | 1,076 (1.2%) | 585 (0.5%) | | Stroke | 325 (0.7%) | 1,572 (1.2%) | 86 (0.7%) | 824 (0.9%) | 887 (0.8%) | | Hemorrhagic stroke | 55 (0.1%) | 231 (0.2%) | 13 (0.1%) | 181 (0.2%) | 102 (0.1%) | | Ischemic stroke | 96 (0.2%) | 533 (0.4%) | 33 (0.3%) | 244 (0.3%) | 253 (0.2%) |
| | Nutritional and metabolic diseases, n (%) | | | | | | | Diabetes mellitus | 1,521 (3.4%) | 21,066 (15.9%) | 1,323 (11.0%) | 3,710 (4.0%) | 3,182 (3.0%) | | Dyslipidemia | 1,801 (4.1%) | 8,365 (6.3%) | 766 (6.4%) | 4,778 (5.2%) | 4,251 (4.0%) | | Diseases of the respiratory system, n (%) | | | | | | | Asthma | 440 (1.0%) | 8,504 (6.4%) | 765 (6.4%) | 6,030 (6.6%) | 6,059 (5.7%) | | Diseases of the genitourinary system, n (%) | | | | | | | Erectile dysfunction | 349 (0.8%) | 2,298 (1.7%) | 209 (1.7%) | 1,241 (1.4%) | 927 (0.9%) | | Renal impairment | 263 (0.6%) | 3,485 (2.6%) | 280 (2.3%) | 1,699 (1.9%) | 824 (0.8%) |
| | Co-medication at baseline, n (%) | | | | | | | Anticoagulants | 806 (1.8%) | 1,634 (1.2%) | 194 (1.6%) | 1,255 (1.4%) | 479 (0.4%) | | Anti-anginals | 2,929 (6.6%) | 1,927 (1.5%) | 219 (1.8%) | 2,025 (2.2%) | 862 (0.8%) | | NSAID | 9,682 (21.8%) | 27,903 (21.1%) | 2,570 (21.4%) | 19,723 (21.5%) | 805 (0.8%) | | Platelet aggregation inhibitors | 7,183 (16.2%) | 15,583 (11.8%) | 1,506 (12.5%) | 11,020 (12.0%) | 412 (0.4%) | | Follow-up time (years) | | | | | | | Median (q1; q3) | 0.4 (0.1; 1.9) | 0.8 (0.2; 2.9) | 1.1 (0.2; 3.4) | 0.6 (0.2; 2.5) | 0.3 (0.1; 1.7) | | Min; max | 0.0; 18.0 | 0.0; 17.9 | 0.0; 17.9 | 0.0; 17.9 | 0.0; 17.9 |
|
|
